Archive for the ‘Genetic medicine’ Category
Oracle starts the Oracle Health Sciences Institute (OHSI), in partnership with Sun Labs
♫ Monday, October 11th, 2010The SaaS impact on solution selling for ISVs (via Inner Lining)
♫ Monday, October 11th, 2010Product marketing teams look at the software buying cycle as a consistent series of steps: awareness, consideration, trial, purchase, implementation and renewal. For years, these steps have been manipulated through solution selling where the key to success is control. By knowing the buyer, the steps and the product, a skilled selling team is able to control the process and predict favorable outcomes on a consistent basis. Oracle, SAP and Mic … Read More
via Inner Lining
GE’s healthymagination initiative lead Smart Patient Room to improve patient safety goes live at Bassett Medical Center
♫ Monday, October 11th, 2010GE Healthcare announced that the Smart Patient Room pilot at Bassett Medical Center has been approved by the site’s Institutional Review Board to begin data collection. The innovative technology solution was installed as part of GE’s healthymagination initiative with the goal of helping healthcare providers to reduce patient safety risks and improve patient outcomes.
“GE is developing a unique solution for the healthcare industry that helps hospitals and staff identify and mitigate patient safety risks while offering meaningful solutions to improve patient outcomes,” said Jan De Witte, President & CEO, GE Healthcare Performance Solutions. “GE’s real-time, adaptable solution will provide actionable data to healthcare providers regarding patient safety and potential medical errors which in turn will affect the necessary behavioral changes to avoid preventable errors.”
The Smart Patient Room can collect real-time information from the system to generate actionable data to manage clinical workflow, and uncover opportunities for influencing process and behavioral changes to create a safer patient environment.
ChIP Enrichment Analysis can speed up drug discovery
♫ Monday, October 11th, 2010developers at Mount Sinai develop a New database and software, called ChEA which can speed up drug discovery at Mount Sinai develop a New database and software, called ChEA which can speed up drug discovery
The ChEA software and ChIP-X database is freely available online at:http://amp.pharm.mssm.edu/lib/chea.jsp.
until ChEA was developed, no centralized database integrated results from, for instance, ChIP-seq and ChIP-chip experiments (these are used to identify how “transcription factor” proteins might regulate all genes in humans and mice). Now this new computational method should help streamline how scientists analyze these gene expression experiments
Life Sciences at Oracle Open World 2010
♫ Monday, October 11th, 2010How useful would be the Single-patient clinical trials for improving the hopes of Personalized medicine
♫ Thursday, August 12th, 2010Single patient Clinical Trial are not new idea, FDA did not focus since such trial canot prove the efficacy and safety of medicine over a large pool of patient with sufficient data. But I was forced to re-think after reading the article http://www.technologyreview.in/biomedicine/12537/ why cant we use the the concept mentioned in to overcome the ethical and other challenges in current mode of trials.
So I decided to ask the question to the linkedin audience http://www.linkedin.com/answers/technology/biotech/TCH_BIO/667022-9262868?browseIdx=0&sik=1272969161323&goback=.amq
How useful would be the Single-patient clinical trials for improving the hopes of Personalized medicine
♫ Thursday, August 12th, 2010Single patient Clinical Trial are not new idea, FDA did not focus since such trial canot prove the efficacy and safety of medicine over a large pool of patient with sufficient data. But I was forced to re-think after reading the article http://www.technologyreview.in/biomedicine/12537/ why cant we use the the concept mentioned in to overcome the ethical and other challenges in current mode of trials.
So I decided to ask the question to the linkedin audience http://www.linkedin.com/answers/technology/biotech/TCH_BIO/667022-9262868?browseIdx=0&sik=1272969161323&goback=.amq
Using Stem Cells Scientists Grow a Rat Lung, Humans are Next
♫ Tuesday, June 29th, 2010Scientists grow a rat lung in the laboratory
By LAURAN NEERGAARD (AP) – 4 days ago
WASHINGTON — It's an early step toward one day building new lungs: Yale University researchers took apart and regrew a rat's lung, and then transplanted it and watched it breathe.
The lung stayed in place only for an hour or two, as the scientists measured it exchanging oxygen and carbon dioxide much like a regular lung — but also spotted some problems that will take more research to fix.
Still, the work is a step in the science fiction-sounding hunt for ways to regenerate damaged lungs — although lead researcher Dr. Laura Niklason cautions that it may be 20 or 25 years before a build-a-new-organ approach is ready for people.
The work was reported online Thursday in the journal Science.
Nearly 400,000 people die of lung diseases each year in the U.S. alone, according to the American Lung Association, and lung transplants are far too rare to offer much help.
But how to replicate these spongy organs? Niklason's team stripped an adult rat's lung down to its basic structural support system — its scaffolding — to see if it's possible to rebuild rather than starting completely from scratch.
First, they essentially washed away the different kinds of cells lining that lung. It gradually faded from a healthy red to a white structure of mostly collagen and other connective tissue that maintained the shape and stretchiness of the original lung, even the tubes where airways would be.
This scaffolding is like a universal donor that shouldn't pose rejection problems, said Niklason: "Your collagen and my collagen are identical."
The researchers put the lung scaffolding into a bioreactor, an incubator-style container designed to mimic the environment in which fetal lungs develop, with fluid pumping through them.
Then they injected a mixture of different lung cells taken from a newborn rat. In the bioreactor, those cells somehow migrated to the right spots and grew air sacs, airways and blood vessels.
In short-term implants in four different rats, engineered lungs replaced one of the animals' native lungs and proved 95 percent as efficient at exchanging oxygen and carbon dioxide, Niklason said.
However, among the problems she spotted were small clots that formed inside the engineered lung, a sign that the new cells hadn't grown a thick enough cover in some places.
The biggest challenge: For this approach ever to work without a person's body rejecting the new tissue, scientists would need to use a recipient's own cells, Niklason explained. But there isn't a way yet to cull the kind of personalized stem cells that would be needed, meaning stem cell research must improve first, she said.
This overall approach also worked in a 2008 University of Minnesota experiment that grew a beating rat heart, and Minnesota researcher Dr. Doris Taylor welcomed the Yale lung work.
Separately in Science, a Harvard University team coated a flexible chip with layers of living lung cells, creating a laboratory tool that mimics some of the action of a breathing human lung. The goal: To replace some of the animal studies needed to test how lungs react to environmental toxins or inhaled drugs.
Online: http://www.sciencemag.org
Stem Cell Therapy: Age of Human Cell Engineering is Born
♫ Friday, June 25th, 2010(06-18) 13:42 PDT SAN FRANCISCO -- Dr. Shinya Yamanaka, a stem cell researcher at UCSF's Gladstone Institutes who discovered a technique for transforming adult skin cells into "pluripotent" stem cells without resorting to human embryos, has won Japan's $550,000 Kyoto Prize, an international award that honors scientific, cultural and spiritual contributions to human knowledge.
His discovery resulted in a class of much-sought stem cells that scientists can induce to become virtually any other type of functioning human cell that one day might be used to treat varied diseases or injuries.
During their research, Yamanaka and his colleagues altered the genetics of adult skin cells by inserting four specific viral genes that produce proteins known as transcription factors into the cells. Those proteins in turn yielded other genes that reprogrammed the skin cells so they acquired all the characteristics that made them what are now known as induced pluripotent cells.
Before his discovery, those pluripotent human stem cells could only be harvested from human embryos, a source posing such powerful ethical issues that former President George W. Bush banned virtually all embryonic stem cell research eight years ago. The ban remained in force until President Obama reversed it last year.
Yamanaka, 47, who is attending the annual meeting of the International Society of Stem Cell Research in San Francisco this week, was not told of his award until just before midnight Pacific time on Thursday.
The Kyoto Prize is awarded annually by Japan's Inamori Foundation for major discoveries in many fields of advanced technology, and four other Bay Area scientists have won it in recent years.
They are Leonard Herzenberg, a Stanford geneticist and immunologist who developed a revolutionary cell-sorting machine now crucial to advanced biomedical research; Alan Kay, a Silicon Valley pioneer at Hewlett-Packard who led advanced computing technology for 40 years; Donald E. Knuth, a Stanford information technology expert and specialist in computer programming, language analysis and computerized printing and Richard Karp, a UC Berkeley computer scientist and pioneer in computational biology.
In addition to heading his laboratory at the Gladstone Institute for Cardiovascular Research on the Mission Bay campus of UCSF, Yamanaka is also a professor at Kyoto University, where he began his efforts seeking a way of transforming adult cells.
Besides resolving ethical issues by his achievement, Yamanaka's success also means that the pluripotent stem cells needed to treat a patient's disease can be obtained from the ordinary skin cells of a patient's own body - thus making stem cell therapy possible without the hazards involved in immunologic rejection of cells from other people.
Robert Lanza, chief scientific officer of Advanced Cell Technology and an adjunct professor at Wake Forest University's stem cell research center, said recently that Yamanaka's work "is likely to be the most important stem cell breakthrough of all time."
"The ability to generate an unlimited supply of patient-specific stem cells will revolutionize the future of medicine," Lanza said.
Read more: http://www.sfgate.com
GE Healthcare announces SaaS Electronic Medical Records Management
♫ Saturday, June 19th, 2010http://newsroom.gehealthcare.com/
GE Health Care is rolling out a new, cloud-based platform that makes it easier for physicians with small practices to maintain and keep track of the electronic medical records of their patients. The new SAAS offering is part of GE’s Centricity offering.
Introducing Centricity Advance
Colonnades Family Medicine is running on Centricity Advance, a web-based EMR solution launched today by GE Healthcare and specifically designed for the smaller physician practice.
Unlike most clinical and financial management solutions, Centricity Advance is a web-based service that costs less than a standard client-server software deployment and is maintained and supported with little or no strain on the healthcare provider’s resources, freeing up more time for patient care.
Ideal as a Web-Based Service
The fact that Centricity Advance was designed from the ground up as a web service is significant. Instead of simply providing web-based gateway into a standard EMR application, the Centricity Advance is created with anywhere/anytime access in mind, resulting in an intuitive and efficient interface without sacrificing functionality. Since system management is centralized as part of the Centricity Advance service, small practices don’t have to worry about data protection, updates, equipment failures and other typically stressful responsibilities of user-driven IT management.
Another key feature of Centricity Advance is the Patient Self-Service Portal, which connects patients to their care. By using their own secure password to log in, patients can communicate privately with their doctor and view their own information such as statements, prescriptions and lab results. Patients can also request and confirm appointments, request prescription refills and get automatic reminders for immunizations and lab tests.
22 Million Australian Cloud computing initiative to benefit life science researchers
♫ Saturday, June 19th, 2010The Australian Research Collaboration Service (ARCS) http://www.arcs.org.au has launched its Computer Cloud scheme, a $22 million project funded by the government’s National Collaborative Research Infrastructure Strategy.
More details check http://www.arcs.org.au/index.php/services/cloud-computing
Bob Correll, the chief information officer for the Department of Immigration and Citizenship, said his agency is also looking into using cloud computing for its electronic visa system
GE Healthcare announces SaaS Electronic Medical Records Management
♫ Saturday, June 19th, 2010http://newsroom.gehealthcare.com/
GE Health Care is rolling out a new, cloud-based platform that makes it easier for physicians with small practices to maintain and keep track of the electronic medical records of their patients. The new SAAS offering is part of GE’s Centricity offering.
Introducing Centricity Advance
Colonnades Family Medicine is running on Centricity Advance, a web-based EMR solution launched today by GE Healthcare and specifically designed for the smaller physician practice.
Unlike most clinical and financial management solutions, Centricity Advance is a web-based service that costs less than a standard client-server software deployment and is maintained and supported with little or no strain on the healthcare provider’s resources, freeing up more time for patient care.
Ideal as a Web-Based Service
The fact that Centricity Advance was designed from the ground up as a web service is significant. Instead of simply providing web-based gateway into a standard EMR application, the Centricity Advance is created with anywhere/anytime access in mind, resulting in an intuitive and efficient interface without sacrificing functionality. Since system management is centralized as part of the Centricity Advance service, small practices don’t have to worry about data protection, updates, equipment failures and other typically stressful responsibilities of user-driven IT management.
Another key feature of Centricity Advance is the Patient Self-Service Portal, which connects patients to their care. By using their own secure password to log in, patients can communicate privately with their doctor and view their own information such as statements, prescriptions and lab results. Patients can also request and confirm appointments, request prescription refills and get automatic reminders for immunizations and lab tests.
22 Million Australian Cloud computing initiative to benefit life science researchers
♫ Saturday, June 19th, 2010The Australian Research Collaboration Service (ARCS) http://www.arcs.org.au has launched its Computer Cloud scheme, a $22 million project funded by the government’s National Collaborative Research Infrastructure Strategy.
More details check http://www.arcs.org.au/index.php/services/cloud-computing
Bob Correll, the chief information officer for the Department of Immigration and Citizenship, said his agency is also looking into using cloud computing for its electronic visa system
GSK, MedTrust launch iPhone/iPad app for cancer trials
♫ Friday, June 11th, 2010GlaxoSmithKline has teamed up with MedTrust Online, provider of specialist data and technology to oncologists, to launch CancerTrialsApp, described as “the first free geo locating cancer clinical trials application” for the Apple iPhone and iPad.
The application enables cancer doctors to find and share with their patients information about experimental therapies in clinical trials
GSK, MedTrust launch iPhone/iPad app for cancer trials
♫ Friday, June 11th, 2010GlaxoSmithKline has teamed up with MedTrust Online, provider of specialist data and technology to oncologists, to launch CancerTrialsApp, described as “the first free geo locating cancer clinical trials application” for the Apple iPhone and iPad.
The application enables cancer doctors to find and share with their patients information about experimental therapies in clinical trials
F.D.A. Says Millions Got Unapproved Drugs, Should the new bioequivalence and bioanalytical guidelines for 2010, be made more stringent
♫ Friday, April 16th, 2010Plans by FDA to Adopt stricter standards for Bioequivalence, Bioavailability for generic drugs could sound trouble for Indian Generic Manufactures. Already most of the smaller companies are finding it difficult to get FDA approval letters. QSR Draft Guidance An industry working group has urged the FDA to consider adopting its guidance to outline quality system requirements (QSR) for bioequivalence and bioavailability testing during drug clinical trials.
There was a recent report in NY times that mentioned about several thousand patients receiving nitroglycerin tablets that were not approved by FDA http://www.nytimes.com/2010/03/27/business/27nitro.html
FDA recently evaluated 2070 human studies conducted between 1996 and 2007. These studies compared the absorption of brand name and generic drugs into a person’s body. These studies were submitted to FDA to support approval of generics. The average difference in absorption into the body between the generic and the brand name was only 2.3%. Some generics were absorbed slightly more, some slightly less. This amount of difference would be expected and acceptable, whether for one batch of brand name drug tested against another batch of the same brand, or for a generic tested against a brand name. In fact, there have been studies in which branded drugs were compared with themselves, as well as with a generic. As a rule, the difference for the generic-to-brand comparison was about the same as the brandto- brand comparison” (www.fda.gov/ Drugs/ResourcesForYou/Consumers/ BuyingUsingMedicineSafely/Under standingGenericDrugs/ucm167991. htm)
Fore more updates attend the event below
F.D.A. Says Millions Got Unapproved Drugs, Should the new bioequivalence and bioanalytical guidelines for 2010, be made more stringent
♫ Thursday, April 15th, 2010Plans by FDA to Adopt stricter standards for Bioequivalence, Bioavailability for generic drugs could sound trouble for Indian Generic Manufactures. Already most of the smaller companies are finding it difficult to get FDA approval letters. QSR Draft Guidance An industry working group has urged the FDA to consider adopting its guidance to outline quality system requirements (QSR) for bioequivalence and bioavailability testing during drug clinical trials.
There was a recent report in NY times that mentioned about several thousand patients receiving nitroglycerin tablets that were not approved by FDA http://www.nytimes.com/2010/03/27/business/27nitro.html
FDA recently evaluated 2070 human studies conducted between 1996 and 2007. These studies compared the absorption of brand name and generic drugs into a person’s body. These studies were submitted to FDA to support approval of generics. The average difference in absorption into the body between the generic and the brand name was only 2.3%. Some generics were absorbed slightly more, some slightly less. This amount of difference would be expected and acceptable, whether for one batch of brand name drug tested against another batch of the same brand, or for a generic tested against a brand name. In fact, there have been studies in which branded drugs were compared with themselves, as well as with a generic. As a rule, the difference for the generic-to-brand comparison was about the same as the brandto- brand comparison” (www.fda.gov/ Drugs/ResourcesForYou/Consumers/ BuyingUsingMedicineSafely/Under standingGenericDrugs/ucm167991. htm)
Fore more updates attend the event below